ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Shereen Elhoseiny, Mohamed El-Wakil, Mohamed Fawzy, Aya Abdel Rahman
Background : Genetic variation influencing individual susceptibility to chemical carcinogens is one of the main factors leading to cancer development. The glutathione S-transferases (GSTs) are a family of enzymes belong ing to phase II enzymes involved in det…
Charlene A. Baksh, Martin J. Edelman, Edward A. Sausville, William D. Figg, Hao Zhu, Kenneth S. Bauer
UCN-01 (7-Hydroxystaurosporine) is an investigational anticancer agent that is currently being evaluated as targeted therapy in phase II clinical studies. The aims of this work were to describe the population pharmacokinetics of UCN-01 in patients with advanc…
M. Hu, R. Z. Chen, L. L. Zhu, C. J. Tao, T. G. Wang, X. D. Xia, P. Li, Y. L. Gong, G. M. Lv
Purpose: Aiming at starting the ball rolling and contributing humble effort to promot ing traditional Chinese medicine, we report one successful case of “ GP ” regimen of combining chemotherapy with traditional Chinese medicine decoction ( “ lung description…
Amani Fouad Sorour, Iman Mamdouh Talaat, Tamer Mohammed Abou Youssif, Mohamed Adel Atta
Prostate cancer is a common disease with a multifactorial and complex etiology. It is the most common male malignancy and the second leading cause of death in many countries. The widespread use of PSA testing has increased the detection of this cancer at earl…
Alend Saadi, Didier Roulin, Essia Saiji, Hanifa Bouzourene, Nicolas Demartines, Maurice Matter
Background: Sentinel node (SLN) status is the most important prognostic factor for early-stage melanoma patients. It will influence follow-up and may change therapy. Positive SLNs present different degrees of involvement so that subgroups of patients may have…
Abdulhamid Chaikh, Jean-Yves Giraud, Jacques Balosso
Purpose : The purpose of this work is to study and quantify the differences in calculated dose computed with two algorithms available in treatment planning systems: Pencil Beam Convolution and Clarkson. Material and Methods : Four different types of treatment…
Kanyarat Katanyoo, Kanisa Rongsriyam, Marisa Chongtanakon
Objective : To evaluate the association between pretreatment levels of serum vascular endothelial growth factor (VEGF) and long-term treatment outcomes in patients with locally advanced cervical cancer (LACC). Methods : Thirty-nine patients diagnosed with LAC…
Oleksey P. Kolesnik, Anatoliy I. Shevchenko, Yuriy E. Lyakh, Vitaliy G. Gurianov
Lung cancer is the most common cause of death from oncological diseases all over the world. Primary treatment of patients with the early stage of non-small cell lung cancer is a surgery. However, after surgery 30% - 85% of patients undergo disease progression…
Emma C. Bourton, Piers N. Plowman, Amanda J. Harvey, Sheba Adam Zahir, Christopher N. Parris
A novel treatment for cancer patients with homozygous deletions of BRCA 1 and BRCA 2 is to use drugs that inhibit the enzyme poly(ADP-ribose) polymerase (PARP). Specific inhibition of PARP-1 can induce synthetic lethality in irradiated cancer cells while theo…
Ismail Eldesoky, Ehab M. Attalla, Wael M. Elshemey
This work aimed at evaluating the effect of 6 - and 10-MV photon energies on intensity-modulated radiation therapy (IMRT) treatment plan outcome in different selected diagnostic cases. For such purpose , 19 patients, with different types of non CNS solid tume…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).